In a filing, Poseida Therapeutics Inc revealed its Director MARK GERGEN acquired Company’s shares for reported $0.34 million on Nov 26 ’24. In the deal valued at $2.86 per share,120,000 shares were bought.
H.C. Wainwright initiated its Poseida Therapeutics Inc [PSTX] rating to a Buy in a research note published on January 04, 2023; the price target was $15. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in early January with a ‘”an Overweight”‘ rating. BTIG Research began covering PSTX with “Buy” recommendation on May 18, 2021. William Blair started covering the stock on August 04, 2020. It rated PSTX as “an Outperform”.
Price Performance Review of PSTX
On Tuesday, Poseida Therapeutics Inc [NASDAQ:PSTX] saw its stock jump 227.97% to $9.38. Over the last five days, the stock has gained 238.63%. Poseida Therapeutics Inc shares have risen nearly 179.17% since the year began. Nevertheless, the stocks have risen 243.59% over the past one year. While a 52-week high of $4.27 was reached on 11/26/24, a 52-week low of $1.87 was recorded on 04/16/24. SMA at 50 days reached $2.90, while 200 days put it at $2.98.
Levels Of Support And Resistance For PSTX Stock
The 24-hour chart illustrates a support level at 9.28, which if violated will result in even more drops to 9.19. On the upside, there is a resistance level at 9.44. A further resistance level may holdings at 9.51. The Relative Strength Index (RSI) on the 14-day chart is 90.60, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.53, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 0.44%. Stochastics %K at 46.41% indicates the stock is a holding.
How much short interest is there in Poseida Therapeutics Inc?
A steep rise in short interest was recorded in Poseida Therapeutics Inc stocks on 2024-11-15, dropping by -0.21 million shares to a total of 4.61 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 4.81 million shares. There was a decline of -4.48%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 04, 2020 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $30 price target.
